Market Overview

UPDATE: Deutsche Bank Raines PT to $45 on Medtronic Following Top-Line Beat

Share:
Related MDT
Earnings Scheduled For August 25, 2016
Following Intuitive Surgical's Solid Q2, Citi Asks What's Next
Apple, Ulta, Medtronic, Dollar Stores Lead Thursday's Action Plan (Investor's Business Daily)

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) but increased its price target from $43 to $45.

Deutsche Bank noted, "Top line beats, but EPS in line; Maintain Hold. In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42.75 on Wednesday.

Latest Ratings for MDT

DateFirmActionFromTo
Aug 2016CitigroupInitiates Coverage onBuy
Jun 2016SunTrust Robinson HumphreyMaintainsBuy
Jun 2016Guggenheim SecuritiesInitiates Coverage onNeutral

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Pre-Market Outlook Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!